Yersina enterocolitica bone and joint infections are rare. Over a period of 7 months four patients with deep-seated skeletal infections due to Y: enterocolitica were seen at the University Hospital, Nottingham. Sites of infection included the knee (one patient) the hip (one) and the spine (two). None of the patients had major underlying disease or risk factors for developing invasive Y: enterocolitica infection. The organisms were sensitive to the second-and third-generation cephalosporins, gentamicin and fluoroquinolones. A literature search covering the period 1970-1994 revealed 20 other cases of skeletal infections due to Y: enterocolitica; there was no uniformity in the choice of antimicrobial agent for treating these infections. Oral ciprofloxacin was used as the principal antimicrobial agent in the patients described here and therapeutic success was achieved in three of these patients. Ciprofloxacin should be considered as first line therapy for invasive infections due to Y: enterocolitica.
Introduction
Yersinia enterocolitica is recognised increasingly as an enteric pathogen with a wide array of clinical manifestations that vary both with age and health of the host [l-31. Enterocolitis, the most common presentation, occurs primarily in young children; pseudo-appendicular syndrome, which often mimics acute appendicitis, occurs mainly in older children and young adults; post-infectious manifestations such as reactive arthropathy and erythema nodosum are seen usually in adults.
Less commonly, Y: enterocolitica may cause focal infection at extra-intestinal sites with or without bacteraemia. Cases of exudative pharyngitis [4, 5] , pneumonia, lung abscess, empyema [6-81, liver [9, 101, splenic [ll] , renal [12] or psoas muscle [13] abscesses, endocarditis [ 14-1 51, osteomyelitis [ 16, 171, septic arthritis [18] and meningitis [17] have all been reported. Rarely, in patients with diabetes mellitus, hepatic cirrhosis, blood dyscrasias or in young infants, infection with I: enterocolitica may cause a septicae-mic illness without an obvious focus of infection [2, 11, [19] [20] [21] . Septicaemia caused by transfusion of contaminated blood has also been reported [22, 23] .
The great majority of the gastrointestinal infections caused by Y: enterocolitica are self-limiting and confined to the gut and do not merit antimicrobial therapy in an immunocompetent host. However, in patients with septicaemia or invasive infection, the mortality can be as high as 50% [2, 111, and antimicrobial therapy is warranted [24] . The organism is usually susceptible in vitro to aminoglycosides, cotrimoxazole, chloramphenicol, tetracycline, the third generation cephalosporins and fluoroquinolones but resistant to penicillin, ampicillin and the first generation cephalosporins. Nevertheless, the drug of choice is yet to be identified [l, 241. Septic arthritis or osteomyelitis caused by I: enterocolitica is extremely rare [25] , and experience in the UK of serious infections due to Y: enterocolitica and information on the optimal treatment of such infections is limited. This paper reports three patients with proven and one with strongly suspected deep-seated skeletal infection with Y: enterocolitica encountered over 7 months and reviews other cases reported in the literature.
Minimal inhibitory concentrations were determined by the agar plate dilution method with a multipoint inoculator as described previously [26] .
A search of the English language literature from 1970 to 1994 was conducted via Medline for other reported cases of osteomyelitis and septic arthritis caused by Y: enterocolitica. Additional cases were identified through a literature search via Paperchase, a review of cited articles and a subsequent review of the references noted in those articles.
Case reports Case 1. An 85-year-old retired monk was hospitalised after a 24-h history of right knee pain and rigors on the day of admission. His past medical history included long-standing osteoarthritis of both knees, cholecystectomy, transurethral prostatectomy, anaemia and proctitis of unknown cause. On admission, his temperature was 38°C and his right knee was swollen and tense with a marked reduction in the range of movement. Laboratory findings included: haemoglobin (Hb) 9.9 g/dl; white blood cell (WBC) count 6.2 x lo9/ L; polymorphonuclear leucocyte (PMNL) count of 5.16 x 109/L; platelet count, 170 x 109/L; erythrocytic sedimentation rate (ESR), 22 mm/h. Serum electrolyte concentrations and liver hnction tests were normal.
A diagnosis of septic arthritis of the right knee was made. Microscopy of a needle aspirate of joint fluid showed numerous neutrophils but no organisms or crystals and treatment was started with intravenous coamoxiclav (1.2 g every 8 h). After 48 h, cultures yielded a moderate growth of a 'coliform-type' organism; treatment was changed to cefotaxime (2 g every 8 h) and gentamicin (120 mg once daily). On day 6, the organism was identified as I: enterocolitica (serotype 09; biotype 3) and treatment was changed to oral ciprofloxacin 750 mg twice daily. The knee was washed out arthroscopically on three occasions and I: enterocolitica was isolated on two of these but before ciprofloxacin was started. A serum sample on day 9 had an agglutination titre of 1280 to the Y: enterocolitica isolate.
After 13 days the ciprofloxacin dose was reduced to 500 mg every 12 h. Ciprofloxacin was stopped after 24 days as the WBC count fell to 2.8 x 109/L (PMNL count 1.57 x 109/L). He was discharged home and remained well.
Case 2. A 63-year-old housewife was admitted to a local district general hospital with an 8-week history of low back pain, which in the last 3 weeks had increased in intensity and radiated to her left groin and buttock. She gave a history of occasional night sweats. Her past medical history included pulmonary tuberculosis, degenerative disease of the spine, ischaemic heart disease and asthma. Physical examination was unremarkable except for tenderness in the mid-lumbar spinal region and pain on flexion. There was no neurological deficit. Spinal X-rays and magnetic resonance imaging (MRI) suggested vertebral osteomyelitis and an epidural abscess at L3/4 level. She was transferred to the Spinal Unit at the University Hospital, Nottingham for further management. Laboratory findings included: Hb 11.3 g/dl; WBC count 8.5 x 109/L; PMNL count 5.75 x 109/L; platelet count 284 x 109/L and ESR > 90 mmh. Serum electrolytes and liver function tests were normal. A CT-guided biopsy of the L3/4 disk space yielded 4-5 ml of bloodstained fluid; microscopy showed scanty neutrophils and no organisms, but after 48 h a 'coliform type' organism was isolated. Cefotaxime (2 g every 6 h) and gentamicin (120 mg once daily) were commenced. Four days later, the organism was identified as I: enterocolitica (serotype 0 9 ; biotype 3) and therapy was changed to oral ciprofloxacin (750 mg every 12 h). She made a rapid and uneventful recovery on medical treatment alone and was discharged on ciprofloxacin (750 mg, 12 hourly; reduced to 500 mg, 12 hourly after 4 weeks). Ciprofloxacin was discontinued after 4 months. A serum sample taken 6 days after admission showed an agglutination titre of 2560 against the I:
Case 3. A 14-year-old school girl with idiopathic scoliosis who had undergone corrective surgery and stabilisation with instrumentation in November 1992 was admitted in January 1994 with a 3-month history of increasing pain, redness and swelling over the middorsal region of the spinal scar. In November 1993, she had been admitted to the hospital for 3 days with suspected osteomyelitis and started empirically on intravenous cefotaxime and flucloxacillin. However, bone scan results were equivocal, and antibiotics were discontinued. Since then she had been seen by her general practitioner with 'boils' appearing intermittently at different points in the mid and lower back region of the scar, which were being treated locally with Betadine.
On admission her temperature was 38. Serum electrolytes and liver function tests were normal.
The following day she underwent exploration of her spinal wound. Granulation tissue and pus was evident along the extent of the metalwork and the pedicle screws were loose. As the spine had fused, all the metalwork was removed and the wound was extensively debrided. Gram-staining of the spinal tissue revealed numerous pus cells but no organisms. The patient was commenced on cefotaxime (2g every 8 h) and vancomycin (1 g 12 hourly), as earlier surface swabs taken from the ulcerated areas had yielded coliform bacilli, Staphylococcus aureus and S. epidermidis. After 48 h a 'coliform-type' organism was isolated from spinal tissue and gentamicin (120 mg, 8 hourly) was added to the regimen. The organism was identified subsequently as I: enterocolitica (serotype 05.27; biotype 3); parenteral antibiotics were discontinued and oral ciprofloxacin 500 mg twice daily was commenced. She was discharged 14 days after admission on ciprofloxacin 500 mg, 12 hourly for a further 2 weeks followed by ciprofloxacin 250 mg 12 hourly for 6 weeks. Serum samples taken during admission were negative for I: enterocolitica antibodies but 6 weeks later a serum sample had an agglutination titre of 320.
Case 4. An 80-year-old retired security officer was admitted to the hospital following a stroke, leading to a left-sided hemiparesis. His past medical history included insulin-dependent diabetes mellitus, ischaemic heart disease, congestive cardiac failure and bilateral deep vein thrombosis. Initially he made a good recovery but on day 16 became acutely unwell, with fever and pain in his left leg radiating to the hip. A red inflamed area on the medial aspect of the thigh was diagnosed as thrombophlebitis and he was commenced on cefuroxime (750 mg, 8 hourly) for a presumed chest infection. An ultrasound of the thigh revealed an occluded left great saphenous vein; abdominal ultrasound and echocardiogram were normal.
After 48 h, blood cultures yielded a 'coliform-type' organism and his antimicrobial therapy was changed to cefotaxime (1 g, 8 hourly). The organism was identified as I: enterocolitica (serotype 09; biotype 3) and treatment was changed to oral ciprofloxacin (500 mg every 12 h). However, the patient continued to deteriorate; he remained febrile and complained of increasing pain in the left hip. A clinical diagnosis of septic arthritis was made. In view of his other medical problems, it was considered inappropriate to investigate the hip joint further. He died 10 days after he first become febrile.
Literature review and discussion
The salient features of the cases described here and 20 previously reported cases of skeletal infection due to I:
enterocolitica [8, 1 1, 16-1 8,27401 are summarised in Table 1 .
Epidemiology
Of 20 reported cases of skeletal infections due to I: enterocolitica, only one was from the UK, the remaining patients were from France (six cases), USA (seven cases) and one each from South Africa, Canada, Spain, Greece, Denmark and Italy. There were 12 males and eight females. The mean age of the patients was 49 years (range 6-84 years). The four children were all females ( Table 1 ). The duration of illness in the reported cases was variable, lasting from 1 day to many weeks, similar to our experience with the four patients in the current series. No definite source of infection was identified in any of the four patients reported here. Patients 1 and 2 gave no history of recent gastrointestinal symptoms, intake of high risk foods, or contact with animals. Patient 3 received a blood transfusion in November 1992, at the time of her last spinal surgery, but it is unlikely that she was infected through this route as her symptoms did not start until September 1993. However, she had visited a farm with other school children in July 1993. Patient 4 had been an in-patient in a general medical ward for 16 days before he became acutely unwell with fever for the first time. However, he had an episode of diarrhoea1 illness several weeks before admission.
Pathogenesis
Besides geographic differences in the frequency and distribution of I: enterocolitica infection, there are differences in virulence among I: enterocolitica strains.
Isolates of serotypes 03, 0 9 and 0 8 are the most frequent causes of sporadic human disease worldwide [l] . Serotypes of 14 of the 20 isolates of I: enterocolitica from skeletal infections were documented in the reports reviewed; nine belonged to serotype 0 3 and three to serotype 09. Three of the four isolates in the present series belonged to serotype 09; the serotype 05.27 isolate from patient 3 has not been reported as a cause of skeletal infection, but is known to cause disease in man [41, 42] .
Iron is an essential growth factor for the multiplication of most bacteria, which obtain iron by releasing highaffinity chelators called siderophores. I: enterocolitica is unusual amongst micro-organisms in being unable to produce siderophores, but has appropriate receptors and can use siderophores from other sources [44] . Invasive infections due to I: enterocolitica have been reported most frequently in patients with conditions associated with iron overload, including thalassaemia and haemochromatosis, and immunocompromised patients [2, 10-121. Amongst reported cases of skeletal infection due to I: enterocolitica, three of four children had thalassaemia major, and the fourth child had Gaucher's disease, cirrhosis and had undergone splenectomy ( [46] . None of the four patients in the current series and five patients reported earlier (Cases 3, 7, 11, 18 and 19) had underlying conditions associated with invasive I: enterocolitica infection. Serum ferritin levels measured during the follow-up period in the three living patients in the current series were found to be within normal limits.
Site of infection and diagnosis
All the reported cases of I: enterocolitica skeletal infection were diagnosed by isolating the organism either directly from the site of infection or blood cultures, or both. In the 16 patients in whom blood cultures were documented as being obtained, 10 were positive; in our series blood cultures were positive in only one of the four patients.
Of 10 patients reported with I: enterocolitica septic arthritis, two developed infection in prosthetic joints, and four involved the shoulder, an unusual site of septic arthritis. Nine patients had osteomyelitis, and one patient had both osteomyelitis and septic arthritis. Haematogenous osteomyelitis of the long bones is rare in adults [25] . Cases 12 and 16 (Table l) , both of whom had major underlying diseases, developed osteomyelitis of the femur and tibia, respectively. There has been only one previous report of vertebral osteomyelitis caused by I: enterocolitica (Case 15). We encountered two such patients, one with a complicating epidural abscess.
Treatment
I: enterocolitica isolates frequently produce p-lactamases and are often resistant to penicillin, ampicillin and the first generation cephalosporins [47, 48] . The WHO recommendations for antimicrobial chemotherapy for I: enterocolitica infections include tetracycline, chloramphenicol, gentamicin and cotrimoxazole [49] . More recently, the third generation cephalosporins and the fluoroquinolones, which have excellent in-vitro activity against I: enterocolitica, have been considered as alternatives for treating I: enterocolitica infections [46, 48] . The four Y: enterocolitica isolates from the present report were susceptible to cefuroxime (MIC G 4 mg/L), cefotaxime ( S 0.12), ceftazidime (0.25), imipenem (0.25), gentamicin (1 .O) and ciprofloxacin (0.03). A recent review of 53 documented cases of I: enterocolitica septicaemia between 1985 and 1991 reported a mortality rate of only 7.5%, compared to 50% mortality pre-1971; this success was attributed partly to the use of these newer agents [SO] . However, the authors noted that patients who received third generation cephalosporins had a lower cure rate (85%) and remained febrile for longer (mean 5.8 days) than patients who received fluoroquinolones (cure rate, 100%; fever response, mean 2 days). Individual case reports of failure of cefotaxime treatment in I: enterocolitica invasive infections [5 11 and a poor response to treatment with other cephalosporins (e.g., cefuroxime, ceftazidime and cefoperazone), despite in-vitro activity, have also been noted by others [46, 50] . Furthermore, in a mouse model of systemic infection with I: enterocolitica, a regimen of high dose cefotaxime or imipenem was found to be inferior to gentamicin or doxycycline [52] . Lemaitre et al. [53] , in the same mouse model, showed greater efficacy of fluoroquinolones compared to p-lactam antibiotics in the treatment of murine I: pseudotuberculosis infection and cautioned against third generation cephalosporins for the therapy of human yersiniosis. The reasons for the discrepancy between in-vitro and in-vivo efficacy of the p-lactam antibiotics, including the third generation cephalosporins, in the treatment of I: enterocolitica infections are not clear. A wide variety of antimicrobial agents was used in the treatment of skeletal infections with I: enterocolitica (Table 1 ) , including aminoglycosides (1 2 cases), chloramphenicol (nine), tetracycline (four) and co-trimoxazole (three). A second or a third generation cephalosporin was used at some stage in six of the 20 patients reported. Cefotaxime treatment was considered to have failed clinically and bacteriologically in two cases; case 18 had received cefotaxime for 8 days following removal of the prosthesis yet I: enterocolitica was still isolated from drainage sites; the organism was re-isolated from the shoulder joint aspirate of case 20 despite 16 days of cefotaxime (lg every 8 h). However, second and third generation cephalosporins either alone or in combination were successful in Cases 15, 16, 17 and 19.
Ciprofloxacin was used in only one patient (Case 18) after cefotaxime had failed and the patient had also received courses of piperacillin plus gentamicin and mecillinam. Fluoroquinolones have been used successfully to treat I: enterocolitica septicaemia, liver abscess and pericarditis [45, 54] . Explanations offered for the greater success of this group of agents over the recent p-lactam antibiotics include its excellent invitro activity, superior tissue penetration and intracellular activity.
In the series reported here, oral ciprofloxacin was used as a single agent once the organism was identified as I: enterocolitica. We are not aware of any other report of deep-seated skeletal infection due to I: enterocolitica being treated successfully with oral ciprofloxacin. Ciprofloxacin should be considered as the first line agent for treating invasive infections due to I: enterocolitica. However, close and frequent monitoring of full blood count is warranted when ciprofloxacin is used for a prolonged period, as it may result in leucopenia [5 51.
